Trending...
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- California: Crime is down in San Francisco, key law enforcement partnerships yield successful results
- On his first day in office, Governor Newsom signed an executive order to bring down the cost of prescription drugs by leveraging California's market power.
- California signed a contract with CIVICA to manufacture affordable insulin
- The Governor will seek to manufacture Naloxone through CalRx
DOWNEY, CA – Governor Gavin Newsom, as part of his tour of the State of California, announced that CalRx has secured a contract with a manufacturer (CIVICA), to make $30 insulin available to all who need it. The Governor also announced today that California will seek to manufacture its own Naloxone.
Today's announcement makes good on Governor Newsom's promise on his first day in office, to bring down the price of prescription drugs for Californians and increase accountability and transparency in health care. Californians can learn more about CalRX on the newly launched website.
More on The Californer
- Playwrights Announced For The 2025 Bill And Judy Garrett Finish Line Commission
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- The Swig Company Presents:Re-Discovering Native America: Stories in Motion with The Red Road Project
- California: Governor Newsom honors fallen La Mesa Police Department Officer
- HollywoodActorJobs.com Full-Time Employment Infomercial World Premiere 10/22/25 at Harkins Theatres
WHAT GOVERNOR NEWSOM SAID: "People should not be forced to go into debt to get life saving prescriptions. Through CalRx, Californians will have access to some of the most inexpensive insulin available, helping them save thousands each year. But we're not stopping there – California will seek to make our own Naloxone as part of our plan to fight the fentanyl crisis."
WHY THIS MATTERS: Today's announcement will bring down the price of insulin by about 90%, saving cash-paying patients between $2,000 and $4,000 annually. With CalRx, and unlike private companies, we're getting at the underlying cost – the price is the price, and CalRx will prevent the egregious cost-shifting that happens in traditional pharmaceutical price games. It'll cost us $30 to manufacture and distribute, and that's how much the consumer can buy it for. You don't need a voucher or coupon to access this price, and it's available to everybody regardless of insurance plan. This is a crucial step in not just cutting the cost for the consumer, but cutting costs across the board in order to bring cheaper prescription drugs to all Californians.
"To address the affordability crisis in California, we have to address the high cost of prescription drugs," said Dr. Mark Ghaly, Secretary of the California Health and Human Services Agency. "The CalRx Biosimilar Insulin Initiative will benefit Californians who are today paying too much for a medication that we know is life saving and life altering."
More on The Californer
- Required Reading for Every Business in The Universe! Read this book about this Marketing Math Today!
- California's Cannabis Task Force Seizes and Eradicates Over $222 Million in Illegal Cannabis in Q3 2025
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge
- Governor Newsom announces tax credit awards for new job-creating films shooting in California and generating $1.4 billion for the state's economy
FACT SHEET
KEY DETAILS
- A 10mL vial will be made available for no more than $30 (normally $300)
- A box of 5 pre-filled 3mL pens will be made available for no more than $55 (normally more than $500)
- No new prescription will be needed. Californians will be able to ask for the CalRx generic at their local pharmacy or via mail order pharmacies. Pharmacies must agree to order/stock the product.
- CalRx plans to make biosimilar insulins available for: Glargine, Aspart, and Lispro (expected to be interchangeable with Lantus, Humalog, and Novolog respectively)
WHAT COMES NEXT- As part of the State's Master Plan to Tackle the Fentanyl Crisis, California is exploring potential next products to bring to market, like Naloxone, to aid in the State's effort to combat fentanyl overdoses.
- CIVICA is working with the California Health and Human Services Agency to identify a California-based manufacturing facility
0 Comments
Latest on The Californer
- Farther's Michael Lee Named One of InvestmentNews' Rising Stars of 2025
- Growing Demand for EVA Mats Signals Shift in Car Interior Market
- 4th Annual Holidays In The Village, A European Marketplace
- Moorpark College Named 2025 Pathway Champion for Driving Equity in Transfer Success
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
- Chera TV: The Female-Led Platform Redefining Hollywood's Next Era of Storytelling
- California Student Aid Commission Launches 2026-27 Statewide Financial Aid Cycle at Ventura College
- California: Governor Newsom supports workers as Trump's shutdown hurts the economy
- California strengthens its pipeline for good-paying jobs, providing $25 million to train more than 22,000 workers through apprenticeship programs
- Why Voting "No on Prop 50" Makes Sense
- Hollywood In Pixels Celebrates the 8th Annual Silver Pixel Awards and Announces 2025 Campaign Pixel Winners Los Angeles, CA — Oct
- While the Trump administration cuts programs to fight hate crimes, California is taking action every day
- The AI Journal Publishes Groundbreaking Article
- Physician Calls for States Nationwide to Ensure ADA Compliance in Independent Commissions
- MEDIA ADVISORY - Strengthening Children's Mental Health Across New Jersey
- Culinage Launches to Preserve Family Recipes and the Stories Behind Them
- NumberSquad Launches Year‑Round Tax Planning Package for Small Businesses and the Self‑Employed
- GlexScale launches a unified model for sustainable SaaS expansion across EMEA
- SwagHer Society Launches to Help Black Women Be Seen and Supported
- Why Hybrid Work Makes Mileage Tracking Harder